method
estim
effect
reproduct
number
yf
angola
use
diseas
natur
histori
case
report
data
simpl
mathemat
model
yf
transmiss
calcul
infect
attack
rate
iar
proport
popul
infect
cours
epidem
vari
level
transmiss
fivefold
fractionaldos
vaccin
efficaci
two
vaccin
scenario
random
vaccin
hypothet
popul
complet
suscept
ii
kinshasa
vaccin
campaign
julyaugust
differ
age
cutoff
fractionaldos
vaccin
find
estim
effect
reproduct
number
earli
angola
outbreak
vaccin
action
allornoth
ie
proport
vaccine
receiv
complet
remaind
receiv
protect
nfold
fraction
dramat
reduc
iar
long
efficaci
exce
benefit
threshold
becom
stringent
vaccin
action
leaki
ie
suscept
vaccine
reduc
factor
equal
vaccin
efficaci
age
cutoff
fractionaldos
vaccin
chosen
kinshasa
vaccin
campaign
name
year
provid
largest
reduct
iar
efficaci
fivefold
fractionaldos
vaccin
exce
yellow
fever
yf
resurg
angola
threaten
spread
countri
rel
low
yf
vaccin
coverag
juli
yf
case
export
angola
kenya
case
china
drc
rais
concern
yf
could
resurg
popul
compet
vector
present
vaccin
coverag
low
inde
drc
alreadi
declar
yf
epidem
kinshasa
two
provinc
broad
band
saharan
africa
north
namibia
zambia
risk
http
wwwcdcgovyellowfevermapsafricahtml
much
northern
portion
south
america
http
wwwcdcgovyellowfevermapssouthamericahtml
global
commun
increasingli
concern
risk
yf
emerg
asia
diseas
curious
absent
despit
seemingli
amen
condit
safe
highli
effect
liveattenu
vaccin
yf
howev
global
emerg
stockpil
yf
vaccin
maintain
approxim
million
dose
alreadi
deplet
twice
angola
outbreak
throughput
million
dose
per
month
yf
vaccin
suppli
inadequ
given
larg
urban
popul
risk
yf
infect
respons
shortag
dose
fraction
propos
maxim
public
health
benefit
avail
yf
vaccin
dose
fraction
smaller
amount
antigen
would
use
per
dose
order
increas
number
person
vaccin
given
quantiti
vaccin
strategi
previous
propos
extend
prepandem
influenza
vaccin
suppli
dose
fraction
consist
adopt
equiti
yf
vaccin
access
would
also
enhanc
within
across
countri
risk
peopl
could
benefit
vaccin
without
depriv
other
inde
follow
sage
endors
june
recommend
dose
fraction
emerg
yf
vaccin
campaign
julyaugust
vaccin
million
peopl
kinshasa
million
anterior
angola
million
along
drcangola
corridor
specif
million
standarddos
vaccin
would
alloc
kinshasa
standarddos
vaccin
would
given
children
age
month
year
remain
alloc
fraction
fivefold
administ
rest
popul
evid
base
fractionaldos
yf
vaccin
built
upon
two
studi
compar
safeti
immunogen
standarddos
fivefold
fractionaldos
yf
vaccin
first
random
noninferior
trial
show
ml
intraderm
id
vaccin
yf
vaccin
equal
safe
immunogen
compar
standard
subcutan
vaccin
estim
initi
reproduct
number
yf
outbreak
angola
averag
reproduct
number
among
case
develop
symptom
one
serial
interv
vaccin
campaign
began
affect
diseas
transmiss
see
figur
fraction
assum
vaccin
efficaci
nfold
fractionaldos
vaccin
n
increas
linearli
amount
antigen
vaccin
see
appendix
explan
potenti
increas
vaccin
wastag
dosespar
would
mostli
due
unus
reconstitut
vaccin
increas
vaccin
failur
due
inexperi
intraderm
administr
among
vaccin
set
mass
vaccin
campaign
wastag
due
unus
vaccin
dose
like
neglig
vaccin
session
larg
infect
attack
rate
use
iar
outcom
measur
evalu
impact
dose
fraction
calcul
iar
use
classic
final
size
approach
exact
directli
transmit
type
diseas
approxim
vectorborn
diseas
nonetheless
dose
vaccin
given
children
age
month
year
suffici
vaccin
unvaccin
children
age
rang
remain
alloc
fraction
onefifth
standard
dose
given
rest
popul
compar
outcom
vaccin
administ
standard
dose
strategi
ii
accord
dosespar
strategi
altern
age
cutoff
fractionaldos
vaccin
rang
year
strategi
f
latter
let
z
age
cutoff
p
z
proport
popul
target
standarddos
vaccin
given
standarddos
vaccin
coverag
v
proport
popul
receiv
standarddos
fractionaldos
vaccin
respect
therefor
effect
vaccin
coverag
vaccin
campaign
immedi
campaign
ie
end
june
see
appendix
calcul
detail
sponsor
studi
role
studi
design
data
collect
data
analysi
write
report
decis
publish
author
access
data
correspond
author
final
respons
submit
public
result
reproduct
number
yellow
fever
angola
figur
show
initi
reproduct
number
yf
angola
ci
mean
mosquito
lifespan
day
respect
estim
may
reflect
partial
immun
due
prior
vaccin
exposur
among
popul
estim
around
angola
popul
vaccin
yf
epidem
see
appendix
calcul
detail
assum
basic
reproduct
number
futur
outbreak
anoth
popul
would
rang
due
vari
vector
ecolog
level
preexist
immun
popul
figur
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
r
respect
short
dose
fraction
reduc
iar
dose
vaccin
suppli
insuffici
halt
diseas
transmiss
ii
fractionaldos
vaccin
efficaci
vaccin
action
leaki
benefit
threshold
efficaci
nfold
fraction
dose
necessari
reduc
iar
higher
increas
transmiss
intens
figur
occur
leaki
model
infecti
bite
assum
less
like
caus
infect
host
vaccin
probabl
infect
grow
person
receiv
infecti
bite
figur
show
leaki
model
vaccin
action
dose
fraction
much
less
benefici
vaccin
action
leaki
efficaci
modest
r
high
see
appendix
mathemat
detail
recent
studi
suggest
mosquito
bite
rate
individu
age
time
higher
age
perform
sensit
analysi
show
result
unaffect
heterogen
see
hetereogen
bite
rate
appendix
detail
vaccin
campaign
kinshasa
estim
vaccin
coverag
kinshasa
end
june
vaccin
campaign
began
assess
robust
conclus
dose
fraction
like
benefici
possibl
fact
efficaci
fraction
dose
lower
anticip
consid
possibl
fivefold
fraction
dose
fail
immun
proport
recipi
find
long
least
recipi
fulli
immun
vaccin
peopl
would
immun
vaccin
five
time
mani
peopl
onefifth
dose
populationwid
benefit
higher
coverag
would
outweigh
lower
efficaci
fraction
dose
individu
vaccine
even
unlik
opinion
fraction
dose
would
substanti
less
efficaci
accord
leaki
model
vaccin
individu
imperfectli
protect
infect
infecti
bite
probabl
infect
bite
reduc
vaccin
proport
see
appendix
detail
case
howev
found
especi
hightransmiss
area
fractionateddos
vaccin
would
need
efficaci
provid
benefit
standard
dose
analysi
intend
recommend
extend
coverag
point
knowingli
compromis
efficaci
rather
analysi
indic
strategi
fraction
dose
provid
equival
immunogen
standard
dose
would
greatli
benefici
efficaci
equival
standard
dose
would
still
benefici
unexpectedli
efficaci
somewhat
lower
standard
dose
use
fivefold
fraction
exampl
strategi
best
evid
base
equal
immunogen
howev
data
suggest
fivefold
fraction
could
equal
immunogen
cours
benefit
fraction
would
greater
fivefold
fraction
logist
possibl
compar
efficaci
consid
fraction
dose
resid
area
high
risk
transmiss
anoth
group
interest
travel
must
also
consid
longev
respons
lower
level
exposur
detail
discuss
equiti
outsid
scope
model
paper
cost
fractionaldos
strategi
depend
rout
administr
could
potenti
substanti
less
expens
per
vaccin
recipi
ccbynd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
simpl
model
sever
limit
assum
homogen
mix
popul
reason
least
local
vectorborn
diseas
also
fix
particular
valu
r
calcul
assum
valu
maintain
epidem
swept
popul
realiti
r
vari
season
vector
abund
extrins
incub
period
factor
vari
exist
hightransmiss
season
might
enhanc
benefit
fractionaldos
vaccin
importantli
premium
achiev
high
vaccin
coverag
peak
transmiss
maxim
impact
transmiss
limit
suppli
constraint
could
partial
reliev
fraction
systemat
review
search
pubm
googl
scholar
june
term
yellow
fever
vaccin
dose
spare
find
report
random
trial
yellow
fever
yf
vaccin
efficaci
full
lower
dose
three
rel
recent
studi
suggest
similar
immunolog
respons
fivefold
fraction
compar
current
dose
antigen
level
sever
recent
perspect
articl
propos
dosespar
strategi
respons
current
shortag
knowledg
first
studi
test
robust
strategi
term
epidemiolog
impact
uncertainti
surround
fractionaldos
yf
vaccin
efficaci
mode
action
eg
allornoth
leaki
ad
valu
studi
estim
reproduct
number
yf
epidem
angola
studi
first
provid
estim
transmiss
yf
urban
set
result
support
grow
evid
dosespar
strategi
adopt
option
extend
current
spars
yf
vaccin
suppli
ccbynd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
reproduct
number
r
assum
mean
mosquito
lifespan
day
respect
red
data
point
correspond
case
use
estim
initi
reproduct
number
case
symptom
onset
one
mean
serial
interv
vaccin
campaign
began
affect
diseas
transmiss
assum
day
start
campaign
account
time
take
adapt
immun
develop
orang
purpl
horizont
bar
indic
length
mean
mosquito
lifespan
serial
interv
scale
xaxi
respect
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
immun
function
standarddos
vaccin
coverag
v
standarddos
vaccin
solid
curv
fivefold
fractionaldos
vaccin
dash
curv
b
infect
attack
rate
iar
standarddos
vaccin
fivefold
fractionaldos
vaccin
iar
reduc
effect
vaccin
coverag
reach
herd
immun
threshold
absolut
reduct
iar
v
increas
kink
appear
herdimmun
threshold
attain
everyon
vaccin
fivefold
fractionaldos
vaccin
ie
v
fivefold
fractionaldos
vaccin
coverag
attain
herd
immun
threshold
low
fractionaldos
vaccin
efficaci
second
kink
appear
v
larg
enough
fractionaldos
vaccin
attain
herdimmun
threshold
due
increas
n
result
lower
fraction
name
n
rel
reduct
iar
ccbynd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
estim
effect
reproduct
number
yf
angola
use
wallinga
teuni
method
estim
reproduct
number
cours
yf
outbreak
angola
daili
number
confirm
case
record
april
angola
situat
report
assum
case
attribut
local
transmiss
ie
import
case
let
date
symptom
onset
case
rel
likelihood
case
infect
case
j
assum
r
normal
distribut
approxim
confid
interv
estim
serial
interv
distribut
yf
assum
latent
period
incub
period
human
infect
yf
suppos
infect
individu
becom
infecti
time
let
time
infecti
individu
bitten
compet
mosquito
becom
infect
time
mosquito
becom
infecti
time
mosquito
bite
infect
human
host
probabl
distribut
function
serial
interv
ccbynd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
h
p
probabl
human
infecti
period
exce
day
mean
infecti
durat
mean
day
extrins
incub
period
degre
celsiu
weibul
distribut
mean
day
cov
probabl
mosquito
still
aliv
day
get
infect
intrins
incub
period
lognorm
distribut
mean
day
cov
calcul
assum
infecti
period
human
exponenti
distribut
mean
day
mosquito
lifespan
exponenti
distribut
mean
vari
week
http
wwwdenguegovsgsubjectasp
assum
extrins
incub
period
follow
weibul
distribut
paramet
exp
temperatur
degre
celsiu
estim
ref
assum
intrins
incub
period
follow
lognorm
distribut
paramet
estim
ref
assum
vaccin
efficaci
nfold
fractionaldos
vaccin
n
increas
linearli
amount
antigen
vaccin
proport
n
gener
vaccin
efficaci
nfold
fractionaldos
vaccin
n
n
n
increas
linearli
amount
antigen
vaccin
special
case
benefit
threshold
simplifi
next
provid
mathemat
detail
iar
calcul
gener
case
group
let
vaccin
action
leaki
groupspecif
iar
obtain
solv
equat
alejandro
costa
target
popul
size
kinshasa
around
million
potenti
million
addit
peopl
adjac
area
million
dose
vaccin
administ
children
age
month
year
standard
dose
suffici
vaccin
unvaccin
children
age
rang
rest
vaccin
stockpil
administ
rest
popul
fivefold
fractionaldos
vaccin
consid
altern
age
cutoff
dose
vaccin
assum
vaccin
stockpil
suffici
vaccin
individu
kinshasa
yet
vaccin
june
consid
allornoth
yf
vaccin
action
mechan
like
leaki
vaccin
action
model
follow
reason
base
limit
evid
immunogen
fraction
dose
date
consid
unlik
reduc
dose
fivefold
perhap
current
prepar
would
result
dramat
lower
efficaci
leaki
type
visual
inspect
data
dose
fraction
trial
vaccin
brazil
show
dose
standard
dose
distribut
serolog
respons
indistinguish
standard
dose
suggest
efficaci
nearli
equival
full
dose
confirm
analysi
peak
viremia
equival
standard
dose
dose
full
dose
fraction
confirm
peak
cytokin
respons
compar
standard
dose
cytokin
test
least
fraction
dose
even
lower
dose
proport
seroconvert
vaccin
lower
observ
full
dose
antibodi
respons
among
seroconvert
appear
similar
dose
data
collect
suggest
approxim
fraction
dose
vaccin
respons
equival
fraction
may
failur
induc
substanti
respons
fraction
recipi
neutral
antibodi
titr
respond
compar
pattern
consist
ornoth
model
copyright
holder
preprint
peerreview
authorfund
ccbynd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
